The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
The antiviral is just about positive in a moderate Covid-19 study, but paradoxically only as a limited regimen.
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
The latest addition to remdesivir’s Covid-19 dataset paints a confusing picture, but it's not necessarily bad.
A world desperate to know whether remdesivir will blunt Covid-19 received another hint today, and this time the news was more encouraging.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.